In addition, as crossing the blood–brain barrier (BBB) is an important aspect of treatments of neurodegenerative diseases such as AD, we tested several single GLP‐1 and dual GLP‐1/GIP receptor agonists to study to what degree they are able to penetrate the BBB to reach the CNS. Here, GLP1R is linked to Alzheimer disease.